1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 48,000 | 48,620 | 13:04 | |
| 48,140 | 48,520 | 04.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Gubra A/S: Gubra announces achievement of milestone from AbbVie following initiation of a Phase 2 clinical trial of ABBV-295, a long-acting amylin analog | 242 | GlobeNewswire (Europe) | ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists. Under Gubra's license agreement with AbbVie... ► Artikel lesen | |
| GUBRA Aktie jetzt für 0€ handeln | |||||
| 20.08. | Gubra H1 2026 slides: pipeline advances as CRO returns to profit | 30 | Investing.com | ||
| 20.08. | Gubra A/S: Interim report H1 2026: Strong clinical pipeline momentum and business execution position Gubra for an exciting period ahead | 494 | GlobeNewswire (Europe) | GUB-UCN2, Gubra's next potential mega program, advanced into clinical development with initiation of a comprehensive Phase 1/2a trial.Partnered obesity programs advancing into Phase 2, with Boehringer... ► Artikel lesen | |
| 28.07. | Gubra A/S: Gubra announces initiation of ambitious Phase 1/2a clinical trial of lead asset GUB-UCN2 in obesity | 533 | GlobeNewswire (Europe) | Gubra today announced the initiation of the first-in-human trial of GUB-UCN2, the company's next mega program, with the first participant completing the first visit. The ambitious Phase 1/2a clinical... ► Artikel lesen | |
| 16.07. | Gubra A/S: Boehringer Ingelheim initiates Phase 2 clinical trial of Gubra-originated triple receptor agonist for people living with overweight and obesity | 540 | GlobeNewswire (Europe) | Gubra today announces that its partner Boehringer Ingelheim has initiated a Phase 2 clinical trial of BI 3034701, an investigational, potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist... ► Artikel lesen | |
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 398 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 06.05. | Gubra Q1 2026 slides: obesity pipeline advances amid CRO headwinds | 24 | Investing.com | ||
| 06.05. | Gubra Q1 2026: Fortschritte in der Adipositas-Pipeline bei Gegenwind im CRO-Geschäft | 56 | Investing.com Deutsch | ||
| 06.05. | Gubra A/S: Trading statement Q1 2026: Continued advancement of Biotech portfolio | 670 | GlobeNewswire (Europe) | Today, Gubra releases its results for the first quarter of 2026, building on a record year in 2025. In the quarter, we advanced our Biotech business, not least shown by strong results and progress for... ► Artikel lesen | |
| 28.04. | Gubra A/S: Boehringer Ingelheim advances Gubra originated obesity triple agonist peptide into Phase 2 development | 972 | GlobeNewswire (Europe) | Gubra today notes that its partner Boehringer Ingelheim plans to initiate Phase 2 clinical development in mid-2026 of BI 3034701, an investigational, potential first-in-class triple GLP-1, GIP and NPY2... ► Artikel lesen | |
| 09.03. | Gubra A/S: AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog | 883 | GlobeNewswire (Europe) | Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant... ► Artikel lesen | |
| 27.02. | Gubra A/S: Annual Report 2025: A record year | 930 | GlobeNewswire (Europe) | Today, Gubra releases its Annual Report for 2025 showing the strongest financial results in Gubra's history. Group revenue and operating profit amounted to DKK 2.6 billion and DKK 2.2 billion, respectively.... ► Artikel lesen | |
| 26.02. | Gubra A/S: Gubra submits clinical trial application for First-in-Human study of lead asset GUB-UCN2 | 948 | GlobeNewswire (Europe) | Gubra today announces that a clinical trial application (CTA) for the first-in-human study of GUB-UCN2, the company's lead asset for high quality weight loss, has been submitted to the Competent Authority... ► Artikel lesen | |
| 10.02. | Gubra A/S: Gubra launches Gubra Ventures and appoints Zoë Johnson to lead new venture creation unit | 472 | GlobeNewswire (Europe) | Gubra today announced the launch of Gubra Ventures, a new business unit focused on creating independent biotechnology companies from high-quality scientific innovation. Zoë Johnson has been appointed... ► Artikel lesen | |
| 08.01. | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | 539 | GlobeNewswire (Europe) | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| 05.01. | Gubra A/S: Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer | 612 | GlobeNewswire (Europe) | Gubra today announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO). Dr. Langenickel brings more than two decades of experience in big pharma and biotech... ► Artikel lesen | |
| 02.01. | Gubra A/S: Gubra Announces Expansion of Facilities to Support Continued Growth Across Its Businesses | 1.251 | GlobeNewswire (Europe) | Gubra A/S ("Gubra") today announced a significant expansion of its laboratory and office facilities at DTU Science Park, located in immediate proximity to the company's headquarters in Hørsholm, Denmark.... ► Artikel lesen | |
| 16.12.25 | Gubra A/S: Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism | 471 | GlobeNewswire (Europe) | Gubra A/S ("Gubra"), a company specialized in peptide-based drug discovery, and Camurus AB ("Camurus"), an international, science-led biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| 08.12.25 | Gubra A/S: Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development | 771 | GlobeNewswire (Europe) | · Favorable Phase I profile and encouraging weight loss signals of potential first-in-class triple agonist BI 3034701 supports further development
Gubra partner Boehringer Ingelheim today announced... ► Artikel lesen | |
| 10.11.25 | Reporting of Transactions Made by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them in Gubra A/S' Shares | 530 | ACCESS Newswire | HØRSHOLM, DK / ACCESS Newswire / November 10, 2025 / Gubra (CPH:GUBRA)Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,55 | +0,22 % | BioNTech-Aktie: mRNA-Schock - wie groß ist der Schaden? | Die BioNTech-Aktie verliert am Freitag zeitweise zweistellig und fällt zuletzt um rund -8% auf etwa 102 US$. BioNTech und Entwicklungspartner Genentech beenden eine Phase-2-Studie mit der personalisierten... ► Artikel lesen | |
| EVOTEC | 3,212 | -1,89 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| BB BIOTECH | 58,50 | +0,17 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,006 | -6,25 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| VALNEVA | 2,977 | +0,61 % | Valneva setzt auf Impfstoff-Innovation als Basis für langfristiges Wachstum | ||
| AMGEN | 376,90 | +0,13 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| EPIGENOMICS | 0,925 | +2,78 % | PTA-News: Epigenomics AG: Kapitalerhöhung in Höhe von EUR 219.244,00 vollständig gezeichnet | DJ PTA-News: Epigenomics AG: Kapitalerhöhung in Höhe von EUR 219.244,00 vollständig gezeichnet
Unternehmensmitteilung für den Kapitalmarkt
Epigenomics AG: Kapitalerhöhung in Höhe von EUR... ► Artikel lesen | |
| NOVAVAX | 8,740 | -0,57 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| STRYKER | 261,30 | +0,11 % | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| BIOGEN | 189,50 | -0,34 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| BIOFRONTERA | 2,400 | -3,23 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,490 | +1,22 % | Heidelberg Pharma baut ADC-Partnerschaft mit Huadong Medicine aus | Heidelberg Pharma erweitert die Zusammenarbeit mit seinem strategischen Partner und zweitgrößten Aktionär Huadong Medicine aus China. Beide Unternehmen wollen gemeinsam neue Antikörper-Wirkstoff-Konjugate... ► Artikel lesen | |
| ILLUMINA | 187,78 | -0,04 % | S&P Dow Jones Indices: Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 | NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices... ► Artikel lesen |
GUBRA A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,41 % bei einem Aktienkurs von 48,540 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUBRA A/S finden Sie auf Wallstreet Online.